AU2001293819A1 - Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug - Google Patents

Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Info

Publication number
AU2001293819A1
AU2001293819A1 AU2001293819A AU9381901A AU2001293819A1 AU 2001293819 A1 AU2001293819 A1 AU 2001293819A1 AU 2001293819 A AU2001293819 A AU 2001293819A AU 9381901 A AU9381901 A AU 9381901A AU 2001293819 A1 AU2001293819 A1 AU 2001293819A1
Authority
AU
Australia
Prior art keywords
cytokine
selectokine
target
fusion protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293819A
Inventor
Matthias Grell
Dieter Moosmayer
Klaus Pfizenmaier
Peter Scheurich
Thomas Wust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfzenmaier Klaus
Universitaet Stuttgart
Original Assignee
Universitaet Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Stuttgart filed Critical Universitaet Stuttgart
Publication of AU2001293819A1 publication Critical patent/AU2001293819A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001293819A 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug Abandoned AU2001293819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (en) 2000-09-15 2000-09-15 An antibody-TNF-TNF inhibitor fusion protein (TNF selectokine) as a target-specific procytokine for tumor therapy
DE10045592 2000-09-15
PCT/EP2001/010730 WO2002022833A1 (en) 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Publications (1)

Publication Number Publication Date
AU2001293819A1 true AU2001293819A1 (en) 2002-03-26

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293819A Abandoned AU2001293819A1 (en) 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Country Status (22)

Country Link
US (1) US20040053829A1 (en)
EP (1) EP1317556A1 (en)
JP (1) JP2004508828A (en)
KR (1) KR20030048041A (en)
CN (1) CN1214115C (en)
AU (1) AU2001293819A1 (en)
BG (1) BG107613A (en)
BR (1) BR0113928A (en)
CA (1) CA2422759A1 (en)
DE (1) DE10045592A1 (en)
EE (1) EE200300100A (en)
HR (1) HRP20030192A2 (en)
HU (1) HUP0301693A3 (en)
IL (1) IL154185A0 (en)
MX (1) MXPA03002229A (en)
NO (1) NO20031185L (en)
PL (1) PL360540A1 (en)
RU (1) RU2003106429A (en)
SK (1) SK2812003A3 (en)
WO (1) WO2002022833A1 (en)
YU (1) YU18903A (en)
ZA (1) ZA200302008B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
PE20021080A1 (en) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER
DE10144252A1 (en) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanoparticles with biologically active TNF immobilized on them
DE10247755B4 (en) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selective local activation of members of the TNF receptor family by systemically inactive non-antibody TNF-ligand fusion proteins
CA2515100A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006117910A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (en) * 2005-08-03 2007-02-08 Universität Stuttgart CTL prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
US20210260163A1 (en) * 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
SG11202011349PA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin-2 polypeptides and methods of use thereof
EP3794022A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3827079A1 (en) * 2018-07-25 2021-06-02 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP7479383B2 (en) * 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド Masked cytokine polypeptides
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (en) * 1999-01-11 2000-07-13 Falkenberg Frank W Composition for prophylaxis or therapy, particularly as an adjuvant for antitumor vaccines, comprises an active agent bound to an adsorbent

Also Published As

Publication number Publication date
PL360540A1 (en) 2004-09-06
EE200300100A (en) 2005-02-15
HUP0301693A2 (en) 2003-08-28
CN1458977A (en) 2003-11-26
RU2003106429A (en) 2004-08-27
IL154185A0 (en) 2003-07-31
WO2002022833A1 (en) 2002-03-21
HUP0301693A3 (en) 2005-11-28
KR20030048041A (en) 2003-06-18
DE10045592A1 (en) 2002-03-28
EP1317556A1 (en) 2003-06-11
CA2422759A1 (en) 2003-03-17
JP2004508828A (en) 2004-03-25
BR0113928A (en) 2003-07-22
MXPA03002229A (en) 2005-06-20
HRP20030192A2 (en) 2005-10-31
SK2812003A3 (en) 2003-11-04
NO20031185D0 (en) 2003-03-14
NO20031185L (en) 2003-05-05
ZA200302008B (en) 2004-06-25
US20040053829A1 (en) 2004-03-18
CN1214115C (en) 2005-08-10
BG107613A (en) 2003-12-31
YU18903A (en) 2006-05-25

Similar Documents

Publication Publication Date Title
AU2001293819A1 (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001259063A1 (en) Albumin fusion proteins
AU2001232799A1 (en) Protein c derivatives
AU2001249395A1 (en) Isolated instructions for isolated execution
AU2001291049A1 (en) Defensin-antigen fusion proteins
AU2002211663A1 (en) Nf-$g(k)b inhibitors
WO2001098968A8 (en) Architecture for anonymous trading system
AU2002224884A1 (en) Substituted anthranilic acids
AU2001293538A1 (en) Novel protein tyrosine phosphatase inhibitor
AU2002238194A1 (en) Means for making mitre joints
AU2001291050A1 (en) Viral chemokine-tumur antigen fusion proteins
AU2002232803A1 (en) Expression system for recombinant proteins
AU2002232707A1 (en) Transmembrane proteins
AU2001220281A1 (en) Rollerboard for road-skiing
AU1672499A (en) Proteinase inhibitor fusion proteins
AU2472501A (en) Methods for protein transfer
AU2002221132A1 (en) Novel antibody
AU2590099A (en) Protein folding inhibitors
AU2001244863A1 (en) Apoptin-associating protein
AUPQ931500A0 (en) System for trading produts
AU2001236058A1 (en) Preparations for chondrogenesis
AU2001263445A1 (en) Methods for protein design
AU2001295042A1 (en) Anti-stilbene antibodies
AU2002215161A1 (en) An assay for rhabdovirus inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application